Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Friday 20 September, 2019

BkofA Merrill Lynch

Form 38.5 (b) - Allergan Plc Replacement

RNS Number : 1869N
Bank of America Merrill Lynch
20 September 2019
 

FORM 38.5 (b) Replacement

 

The Form 38.5 (b) Allergan Plc announcement released on 20/09/2019 under RNS No 1334N has been amended.

 

Amendments are identified with an asterisk (*).

 

The full amended text is shown below.

 

-------------------------------------------------------------------

FORM 38.5(b)

 

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT
RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED INTERMEDIARY
STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

1.

KEY INFORMATION

Name of exempt principal trader

BofA Securities, Inc.

Company dealt in

Allergan PLC

Class of relevant security to which the
dealings being disclosed relate(Note 1)

Common - IE00BY9D5467

Date of dealing

19/09/2019

 

2.

INTERESTS AND SHORT POSITIONS

(a)

Interests and short positions (following dealing) in the class of relevant security
dealt in (Note 2)

Class of relevant security: Common

US00287Y1091


Long

Short

Number

%

Number

%

(1)

Relevant securities

1,098,977

0.335 %

979,372

0.298 %

(2)

Derivatives (other than options):

868,548

0.265%

883,934

0.269%

(3)

Options and agreements to purchase/sell:

761,600

0.232%

596,300

0.182%

Total

2,729,125

0.832%

2,459,606

0.749%

 

(b)

Interests and short positions in relevant securities of the company, other than the
class dealt in (Note 2)

Class of relevant security:



Long

Short

Number

%

Number

%

(1)

Relevant securities

0

0%

0

0%

(2)

Derivatives (other than options):

0

0%

0

0%

(3)

Options and agreements to purchase/sell:

0

0%

0

0%

Total

0

0%

0

0%

3.

DEALINGS (Note 3)

(a)

Purchases and sales

 

Purchase/sale

Number of relevant securities

Price per unit (Note 4)

Purchase

463

 165.78 USD

 Purchase

116

 165.83 USD

 Purchase

632

 165.84 USD

 Purchase

667

 165.85 USD

 Purchase

1,152

 165.86 USD

 Purchase

1,401

 165.87 USD

 Purchase

678

 165.88 USD

 Purchase

845

 165.89 USD

 Purchase

768

 165.9 USD

 Purchase

453

 165.91 USD

 Purchase

446

 165.92 USD

 Purchase

32

 165.926 USD

 Purchase

17

 165.93 USD

 Purchase

192

 165.94 USD

 Purchase

230

 165.95 USD

 Purchase

116

 165.96 USD

 Purchase

159

 165.97 USD

 Purchase

345

 165.98 USD

 Purchase

343

 165.99 USD

 Purchase

409

 166 USD

 Purchase

7,777

 166.01 USD

 Purchase

631

 166.02 USD

 Purchase

1

 166.03 USD

 Purchase

27

 166.04 USD

 Purchase

100

 166.07 USD

 Purchase

172

 166.09 USD

 

Purchase/sale

Number of relevant securities

Price per unit (Note 4)

Sale

1

 165.68 USD

 Sale

5

 165.73 USD

 Sale

1

 165.77 USD

 Sale

4

 165.84 USD

 Sale

104

 165.86 USD

 Sale

100

 165.87 USD

 Sale

40

 165.88 USD

 Sale

205

 165.89 USD

 Sale

200

 165.9 USD

 Sale

109

 165.91 USD

 Sale

43

 165.92 USD

 Sale

32

 165.926 USD

 Sale

4

 165.93 USD

 Sale

63

 165.94 USD

 Sale

25

 165.95 USD

 Sale

159

 165.96 USD

 Sale

17

 165.97 USD

 Sale

2,871

 165.98 USD

 Sale

52

 165.99 USD

 Sale

137

 166 USD

 Sale

7,741

 166.01 USD

 Sale

37

 166.02 USD

 Sale

141

 166.03 USD

 Sale

25

 166.04 USD

 Sale

34

 166.05 USD

 Sale

226

 166.06 USD

 Sale

200

 166.08 USD

 Sale

2

 166.09 USD

 Sale

7

 166.1 USD

Sale

700

 165.72 USD

 

 

(b)

Derivatives transactions (other than options transactions)

Product name,
e.g. CFD

Nature of transaction
(Note 5)

Number of relevant securities
(Note 6)

Price per unit
(Note 4)

N/A

N/A

N/A

N/A

 

(c)

Options transactions in respect of existing relevant securities

(i)

Writing, selling, purchasing or varying

Product name, e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc

Expiry date

Option money paid/ received per unit (Note 4)

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 

(ii)

Exercising

Product name,
e.g. call option

Number of securities

Exercise price per
unit
(Note 4)

N/A

N/A

N/A

 

(d)

Other dealings (including transactions in respect of new securities) (Note 3)

Nature or transaction
(Note 7)

Details

Price per unit
(if applicable)
(Note 4)




N/A

N/A

N/A

N/A

N/A

N/A

 

4.

OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting rights
or future acquisition or disposal of any relevant securities to which any derivative
referred to on this form is referenced. If none, this should be stated.

None

 

Is a Supplemental Form 38.5(b) attached? (Note 8)

Yes

 

Date of disclosure

20/09/2019

Contact name

Tolu Tade

Telephone number

+44207 996 3410

Name of offeree/offeror with which connected

AbbVie Inc

Nature of connection (Note 9)

Advisor to - AbbVie Inc

 

 

 

SUPPLEMENTAL FORM 38.5(b)

 

 

 

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DETAILS OF OPEN POSITIONS

 

(This form should be attached to Form 38.5(b)) OPEN POSITIONS (Note 1)

 

Product name,

e.g. call option

Written or purchased

Number of relevant securities to which the option or derivative relates

Exercise price (Note 2)

Type, e.g. American, European etc.

Expiry date

Call Option

Purchased

      100,000

165 USD

American

20/12/2019

Call Option

Purchased

       60,000

165 USD

American

17/01/2020

Call Option

Written

       91,600

170 USD

American

20/12/2019

Call Option

Written

       10,600

160 USD

American

20/09/2019

Put Option

Purchased

      248,000

55 USD

American

20/12/2019

Put Option

Purchased

       91,600

60 USD

American

20/12/2019

Put Option

Purchased

       10,000

45 USD

American

18/10/2019

Put Option

Purchased

      104,500

50 USD

American

20/09/2019

Put Option

Purchased

       40,000

55 USD

American

20/09/2019

Put Option

Written

      496,000

50 USD

American

20/12/2019

Put Option

Written

       75,000

60 USD

American

21/02/2020

Put Option

Written

       30,600

60 USD

American

20/09/2019

 

 

 

 

Notes

 

1.       Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.

 

2.       For all prices and other monetary amounts, the currency must be stated.

 

For full details of disclosure requirements, see Rules 8 and

38.5 of the Rules. If in doubt, consult the Panel.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEEASNEASXNEFF

a d v e r t i s e m e n t